Stablecoin Development Corp
Close on Oct 19, 2026
- Market cap
- $26.03M
- P/E (TTM)
- –
- Dividend yield
- 477.10%
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Jul 31, 2026 | Before market open | $2.20M | $-1.32 | – |
| Q1 FY2026 Ended Mar 31, 2026 | Apr 6, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 23, 2026 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 16, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 11, 2024 | Before market open | $2.40M | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | $3.70M | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Jul 21, 2020 | Before market open | – | – | – |
| Q2 FY2019 Ended Jun 30, 2019 | Jul 29, 2019 | Before market open | – | – | – |
| Q1 FY2019 Ended Mar 31, 2019 | May 13, 2019 | After market close | – | – | – |
| Q3 FY2015 Ended Sep 30, 2015 | Nov 19, 2015 | Before market open | – | – | – |
| Q4 FY2008 Ended Dec 31, 2008 | Jan 20, 2009 | During market hours | – | – | – |
Press releases
Announcements Stablecoin Development filed with the SEC
In the past year, we completed a comprehensive realignment of our business. We have adopted a capital allocation strategy focused on acquiring digital assets that provide exposure to economic participation within open digital financial networks.
Results of operations · Other events · EX-99.1 to Form 8-K
Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Stablecoin Development Corporation Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “ SDEV ”
Results of operations · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces Name Change to Stablecoin Development Corporation, Reports Initial Staking Rewards, and Provides SKY Token Holdings Update
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces a 1-for-5 Reverse Stock Split
Other events · EX-99.1 to Form 8-K
Our approach anticipates that we may:
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Issues a Reminder of
Regulation FD disclosure · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces One-Time Special Cash Dividend of $0.80 Per Share
Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals to Hold Special Meeting of Stockholders
Material agreement · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal
Acquisition or disposition completed · Executive or director change · Shareholder vote results · Other events · EX-99.1 to Form 8-K
Unaudited Pro Forma Condensed Consolidated Financial Information
Acquisition or disposition completed · Executive or director change · Shareholder vote results · Other events · EX-99.2 to Form 8-K
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
Shareholder vote results · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024
Shareholder vote results · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Signs Definitive Agreement to Sell its Avenova Assets
Material agreement · Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces Pricing of $3.5 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces Closing of $3.87 Million Underwritten Public Offering, Including Partial Exercise of Overallotment Option
Material agreement · Other events · EX-99.2 to Form 8-K
NovaBay Pharmaceuticals Reports Preliminary Second Quarter 2024 Net Revenue
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces Approval of All Proposals at its 2024 Annual Meeting of Stockholders and Provides Other Corporate Updates
Listing notice · Shareholder vote results · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Receives a NYSE American Notice Regarding Stockholder Equity
Listing notice · Other events · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals Announces Agreement to Sell its DERMAdoctor Skincare Business Segment; Announces Preliminary Financial Results for Fourth Quarter and Year Ended December 31, 2023
Material agreement · Results of operations · EX-99.1 to Form 8-K
NovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma ’ s Extensive Distributor Network
Material agreement · Other events · EX-99.1 to Form 8-K